Evidence map›Paper›PMID 41874030›Full record

ArticleAntibodies (Basel, Switzerland)2026

Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort.

Davide Bagnara, Andrea Nicola Mazzarello, Monica Colombo, Ennio Nano, Niccolò Cardente, Fabiana Ferrero, Nadia Bertola, Vanessa Cossu, Fabio Ghiotto, Adalberto Ibatici and 7 more

Abstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Davide BagnaraDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0001-7889-8103
Andrea Nicola MazzarelloDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, Italy.
Monica ColomboMolecular Pathology Unit, IRCCS Azienda Ospedaliera Metroplitana, 16132 Genoa, Italy.ORCID 0000-0001-5512-8106
Ennio NanoMolecular Pathology Unit, IRCCS Azienda Ospedaliera Metroplitana, 16132 Genoa, Italy.ORCID 0009-0003-1479-8121
Niccolò CardenteDepartment of Immunology, University of Oslo, 0424 Oslo, Norway.ORCID 0009-0009-4021-1631
Fabiana FerreroDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, Italy.ORCID 0009-0000-5097-6640
Nadia BertolaMolecular Pathology Unit, IRCCS Azienda Ospedaliera Metroplitana, 16132 Genoa, Italy.ORCID 0000-0003-4591-3260
Vanessa CossuDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-7302-7429
Fabio GhiottoDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-2301-8698
Adalberto IbaticiHematology and Cellular Therapy Unit, Azienda Ospedaliera Metroplitana, 16132 Genova, Italy.
Emanuele AngelucciHematology and Cellular Therapy Unit, Azienda Ospedaliera Metroplitana, 16132 Genova, Italy.ORCID 0000-0002-6512-6080
Antonino NeriScientific Directorate, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.
Massimo GentileHematology Unit, Department of Onco-Hematology, AO of Cosenza, 87100 Cosenza, Italy.
Fortunato MorabitoGruppo Amici Dell'Ematologia Foundation-GrADE, 42100 Reggio Emilia, Italy.ORCID 0000-0002-2585-7073
Manlio FerrariniDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, Italy.
Giovanna CutronaMolecular Pathology Unit, IRCCS Azienda Ospedaliera Metroplitana, 16132 Genoa, Italy.ORCID 0000-0002-3335-1101
Franco FaisDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-6643-7083

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesThe immunoglobulin heavy-chain variable (IGHV) gene repertoire represents a characteristic feature of chronic lymphocytic leukemia (CLL), although its configuration is not well defined at the early disease stages. The IGHV repertoire of a cohort of early CLL patients was analyzed and compared to that of a "real-world" reference cohort.

methodsPatients from the O-CLL1 observational protocol, which enrolled only Binet stage A cases within twelve months from diagnosis, were studied. IGHV/IGHJ rearrangements were sequenced and annotated following ERIC recommendations, and stereotyped subsets were assigned using ARResT/AssignSubsets. The repertoire features were compared with the dataset of a real-world cohort of patients with heterogeneous staging (CTR cohort) and with published early-diagnosis series.

resultsIGHV and IGHJ gene distributions and HCDR3-length profiles in O-CLL1 closely mirrored those of CTR, indicating that the BcR IG repertoire at diagnosis is already defined rather than being selected during disease progression. Mutated IGHV (M-CLL) predominated, with a frequency of stereotyped BcR IG comparable to that of other early-diagnosis cohorts. However, within this conserved framework, subset #4 was over-represented among M-CLL from O-CLL without an increased overall IGHV4-34 gene usage, suggestive of a selective expansion rather than a recombinational bias. Subset #4 cases retained canonical HCDR3 motifs and showed time-to-first-treatment like other M-CLL, likely reflecting the younger age structure of O-CLL1.

conclusionsEarly-diagnosis CLL displays a biased IGHV repertoire with stereotyped configurations characteristic of CLL, including subsets that are rare in the normal B-cell repertoire. These findings support a central role for antigen-driven selection in shaping CLL evolution.

Indexed as

antigen-driven selectionB-cell receptor stereotypychronic lymphocytic leukemiaearly-stage CLLIGHV repertoireImmunogenetics

Identifiers

PMID41874030
PMCPMC13010646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.